Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.54 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324386 | 1.00 | BACE1 (0.54) | BACE1SLC6A11BCHE | |
| SCHEMBL2843604 | 1.00 | BACE1 (0.54) | BACE1SLC6A11BCHE | |
| SCHEMBL2188440 | 1.00 | BACE1 (0.54) | BACE1SLC6A11BCHE | |
| SCHEMBL7305633 | 0.93 | BACE1 (0.60) | BACE1SLC6A11BCHE | |
| SCHEMBL7306846 | 0.93 | BACE1 (0.60) | BACE1SLC6A11BCHE | |
| SCHEMBL3352792 | 0.91 | BACE1 (0.54) | BACE1SLC6A11BCHE | |
| SCHEMBL3352784 | 0.91 | BACE1 (0.54) | BACE1SLC6A11BCHE | |
| SCHEMBL4349878 | 0.89 | FOLH1 (0.45) | BACE1SLC6A11BCHE | |
| SCHEMBL6051163 | 0.89 | FOLH1 (0.45) | BACE1SLC6A11BCHE | |
| SCHEMBL13537983 | 0.89 | BACE1 (0.52) | BACE1SLC6A11BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018015929-A1 | A NOVEL PROCESS FOR THE PREPARATION OF HIV PROTEASE INHIBITOR AND INTERMEDIATES THEREOF | GRANULES INDIA LIMITED (IN) | 2018-01-25 | — | — | WO | disclosed |
| EP-2235008-B1 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-16 | — | — | EP | disclosed |
| US-8350048-B2 | Amide compounds as boosters of antivirals | JANSSEN R&D IRELAND (IE) | 2013-01-08 | — | — | US | disclosed |
| US-20100305073-A1 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | TIBOTEC BVBA | 2010-12-02 | — | — | US | disclosed |
| EP-2235008-A2 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | Tibotec Pharmaceuticals (IE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009071650-A2 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305073-A1 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | CYP3A5, CYP3A4, CYP3A43 | BACE1 823/4885SLC6A11 2155/4885BCHE 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.